Seaport Global Securities Weighs in on Pluristem Therapeutics, Inc.’s Q3 2018 Earnings (PSTI)

Pluristem Therapeutics, Inc. (NASDAQ:PSTI) – Analysts at Seaport Global Securities issued their Q3 2018 EPS estimates for Pluristem Therapeutics in a report released on Friday. Seaport Global Securities analyst V. Bernardino expects that the biotechnology company will post earnings of ($0.09) per share for the quarter. Seaport Global Securities has a “Buy” rating and a $5.00 price objective on the stock.

WARNING: “Seaport Global Securities Weighs in on Pluristem Therapeutics, Inc.’s Q3 2018 Earnings (PSTI)” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://ledgergazette.com/2017/10/10/seaport-global-securities-weighs-in-on-pluristem-therapeutics-inc-s-q3-2018-earnings-psti.html.

Several other analysts have also commented on the company. HC Wainwright set a $4.00 price objective on Pluristem Therapeutics and gave the company a “buy” rating in a report on Thursday, August 17th. Maxim Group set a $2.00 price objective on Pluristem Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 16th. ValuEngine raised Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Finally, Zacks Investment Research lowered Pluristem Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $4.13.

Pluristem Therapeutics (NASDAQ PSTI) remained flat at $1.56 on Monday. 184,896 shares of the stock traded hands. Pluristem Therapeutics has a 1-year low of $1.04 and a 1-year high of $1.65. The stock’s 50 day moving average price is $1.35 and its 200 day moving average price is $1.32. The stock’s market capitalization is $152.06 million.

An institutional investor recently raised its position in Pluristem Therapeutics stock. Jane Street Group LLC grew its position in Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 62.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 108,830 shares of the biotechnology company’s stock after acquiring an additional 41,796 shares during the quarter. Jane Street Group LLC owned about 0.11% of Pluristem Therapeutics worth $134,000 as of its most recent SEC filing. Institutional investors own 4.47% of the company’s stock.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, i

Pluristem Therapeutics, Inc. (NASDAQ:PSTI) – Analysts at Seaport Global Securities issued their Q3 2018 EPS estimates for Pluristem Therapeutics in a report released on Friday. Seaport Global Securities analyst V. Bernardino expects that the biotechnology company will post earnings of ($0.09) per share for the quarter. Seaport Global Securities has a “Buy” rating and a $5.00 price objective on the stock.

WARNING: “Seaport Global Securities Weighs in on Pluristem Therapeutics, Inc.’s Q3 2018 Earnings (PSTI)” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://ledgergazette.com/2017/10/10/seaport-global-securities-weighs-in-on-pluristem-therapeutics-inc-s-q3-2018-earnings-psti.html.

Several other analysts have also commented on the company. HC Wainwright set a $4.00 price objective on Pluristem Therapeutics and gave the company a “buy” rating in a report on Thursday, August 17th. Maxim Group set a $2.00 price objective on Pluristem Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 16th. ValuEngine raised Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Finally, Zacks Investment Research lowered Pluristem Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $4.13.

Pluristem Therapeutics (NASDAQ PSTI) remained flat at $1.56 on Monday. 184,896 shares of the stock traded hands. Pluristem Therapeutics has a 1-year low of $1.04 and a 1-year high of $1.65. The stock’s 50 day moving average price is $1.35 and its 200 day moving average price is $1.32. The stock’s market capitalization is $152.06 million.

An institutional investor recently raised its position in Pluristem Therapeutics stock. Jane Street Group LLC grew its position in Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 62.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 108,830 shares of the biotechnology company’s stock after acquiring an additional 41,796 shares during the quarter. Jane Street Group LLC owned about 0.11% of Pluristem Therapeutics worth $134,000 as of its most recent SEC filing. Institutional investors own 4.47% of the company’s stock.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply